BioCentury: Biotech leaders call on peers to lobby for IRA change

Mar 23

Written By Marshall Bursis

Marshall Bursis

Measuring the damage: IRA’s impact on small molecule drug development

The Well News: Misguided Rating Cancels Rare Disease Patients